ReviewQuantitative imaging in medicine and surgery2023
The application of
Review in Quantitative imaging in medicine and surgery, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Dual-tracer PSMA/FDG PET/CT for lesion detection and risk stratification in biochemical recurrence with negative conventional imaging.European journal of nuclear medicine and molecular imaging · 2026Article
- The value ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Primary clear-cell carcinoma of the liver with gastric antrum metastasis: Integrated management with targeted therapy, immunotherapy and salvage surgery: A case report.Oncology letters · 2026Article
- Value of Multitracer Imaging in Hepatocellular Carcinomas with Different Metastatic Potential.Molecular imaging and biology · 2026Article
- 18F-FDG-PET/CT-negative gastric cancer employs glutamine-based gluconeogenesis and fatty acid oxidation to support tumor growth.Cell death & disease · 2026Article
- Ectopic hepatocellular carcinoma metastasizing to the brain with initial presentation as tumor stroke syndrome: a case report.BJR case reports · 2026Article
- The diagnostic value of 18 F-FAPI-04 PET/CT in unresectable hepatocellular carcinoma: a head-to-head comparison with 18 F-FDG PET/CT.European journal of nuclear medicine and molecular imaging · 2026Article
- Management of Advanced Hepatocellular Carcinoma: A Review and Practical Guide.JCO oncology practice · 2025Review
- Correlation between dual-time-pointQuantitative imaging in medicine and surgery · 2025Article
- Development of a Cyclic TMTP1-Based PET Probe for Visualization of Hepatocellular Carcinoma.ACS medicinal chemistry letters · 2025Article
- Clinically Evident Portal Hypertension Is an Independent Risk Factor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation.Journal of clinical medicine · 2025Article
- Preoperative prediction of microvascular invasion: new insights into personalized therapy for early-stage hepatocellular carcinoma.Quantitative imaging in medicine and surgery · 2024Review
- Prostate-Specific Membrane Antigen Positron Emission Tomography Oncological Applications beyond Prostate Cancer in Comparison to Other Radiopharmaceuticals.Diagnostics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Primary hepatocellular carcinoma (HCC) poses a significant threat to human health. The mean overall survival (OS) of HCC is approximately 15.8 months whereas the 6-month and 1-year OS rates are only 71.6% and 49.7%, respectively. Methods: The PubMed database was searched for all articles on the application of Key Content and Findings: In this review, we re-evaluate the potential hypoxia-dependent uptake mechanism of Conclusions:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.